Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
06/2003
06/19/2003US20030113789 Protease peptides; anticarcinogenic agents; neurotransmitters; antidiabetic agents
06/19/2003US20030113772 DNA encoding human alpha 1 adrenergic receptors and uses thereof
06/19/2003US20030113771 DNA encoding human alpha 1 adrenergic receptors and uses thereof
06/19/2003US20030113750 Diagnosing cancer of urogenital systems using oligonucleotides/peptide nucleic acids or cytosine methylation; matrix assisted laser desorption ionization/electron spray mass spectrometry
06/19/2003US20030113393 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
06/19/2003US20030113366 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
06/19/2003CA2469889A1 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
06/19/2003CA2469858A1 Functionalized higher diamondoids
06/19/2003CA2469340A1 Treating muscle wasting with selective androgen receptor modulators
06/19/2003CA2468892A1 Vitamin d analogues
06/19/2003CA2468544A1 Vanilloid receptor ligands
06/19/2003CA2468156A1 Azolopyrimidinone compounds and their use
06/19/2003CA2467573A1 3-cyanoquinolines as inhibitors of egf-r and her2 kinases
06/19/2003CA2465759A1 Method for administering birb 796 bs
06/19/2003CA2464341A1 Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
06/18/2003EP1319025A2 Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse
06/18/2003EP1319007A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
06/18/2003EP1319003A1 Xanthine phosphodiesterase v inhibitors
06/18/2003EP1318988A2 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
06/18/2003EP1318981A2 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor
06/18/2003EP1318979A1 Cyclopentane derivatives as therapeutic agents
06/18/2003EP1318977A1 Substituted phenylcyclohexane carboxylic acid amides and the use thereof
06/18/2003EP1318830A2 Notch receptor agonists and uses
06/18/2003EP1318821A1 Fluid for haemofiltration
06/18/2003EP1318809A1 Micronized torsemide
06/18/2003EP1255757B1 Amino acid derivatives and use thereof as nep, ace and ece inhibitors
06/18/2003EP1075475B1 Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production
06/18/2003EP0819125B1 Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
06/18/2003CN1425023A Transgenic mice containing TRP gene disruptions
06/18/2003CN1425016A Benzoxathiepino [3,4-b] pyridine derivatives, process for their preparation and their use as medicaments
06/18/2003CN1425009A Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents
06/18/2003CN1424999A Aminoalcohol derivatives
06/18/2003CN1424312A Specific indole compound and its preparation and use in treating and preventing cancers
06/18/2003CN1424109A Use of ginsenoside Rbl
06/18/2003CN1424104A Medicines for treating chronic prostatitis and preparation thereof
06/18/2003CN1424100A Medicines for treating and preventing diabetes and nephrodystrophy
06/18/2003CN1111529C Piperazino derivatives as neurokinin antagonists
06/18/2003CN1111528C Piperazino derivatives as neurokinin antagonists
06/18/2003CN1111414C Use of magnesium salts or magnesium complex as production of medicines
06/18/2003CN1111404C Controlled release oxybutynin formulation
06/17/2003US6579892 Affective disorders; neurotic, stress and somatoform disorders and psychoses, e.g. schizophrenia 3-(3-(6-Methyl-1,2,3,4-tetrahydronaphth-2-ylamino)propylmercap to) -4-methyl-5-phenyl-1,2,4(4H)-triazole
06/17/2003US6579887 Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
06/17/2003US6579883 Fluorinated 3,4-dihydroquinoline derivatives used as NOS inhibitors
06/17/2003US6579874 Substituted azoles
06/12/2003WO2003048129A1 Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same
06/12/2003WO2003048125A1 Aminotetralin derivatives as muscarinic receptor antagonists
06/12/2003WO2003048124A1 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists
06/12/2003WO2003048123A1 Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
06/12/2003WO2003048120A2 2-aryl pyrrologpyrimidines for a1 and a3 receptors
06/12/2003WO2003048116A2 Esters and amides as ppar-alpha agonists ____________
06/12/2003WO2003047625A1 Neural transmission promoters
06/12/2003WO2003047624A1 Cell migration inhibitor
06/12/2003WO2003047608A1 A novel herbal chemical composition for the treatment of cancer
06/12/2003WO2003047588A1 Kit for reducing aching caused by pde-v inhibitors
06/12/2003WO2003047577A2 Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses
06/12/2003WO2003047574A1 Pharmaceutical composition comprising a derivative of 5-phenoxyalkyl-2,4-thiazolidinedione type and a 4-oxobutanoic acid
06/12/2003WO2003047570A1 Benzazole derivatives for the treatment of scleroderma
06/12/2003WO2003047506A2 Peptide agonists of prostate-specific antigen, and uses therefor
06/12/2003WO2003016273A3 Peptide arginals and methods for treating disseminated intravascular coagulation
06/12/2003WO2002047679A3 Nonpeptide agonists and antagonists of vasopressin receptors
06/12/2003WO2002009683A9 Aldosterone blocker therapy to prevent or treat inflammation-related disorders
06/12/2003US20030109752 Purification of racemic mixtures
06/12/2003US20030109675 Therapy for infections; enzyme inhibitors
06/12/2003US20030109578 Treating acute and chronical inflammatory processes in a patent in need thereof which comprises administering to such patent an amount effective therefor of a compound or salt thereof according to claim 1.
06/12/2003US20030109545 Their solvates and/or hydrates exhibiting an affinity and a selectivity for arginine-vasopressin V1b receptors or for both V1b and V1a receptors.
06/12/2003US20030109535 GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure:prodrugs, stereoisomers and drugs
06/12/2003US20030109534 Non-peptide CCR1 receptor antagonists for the treatment of progressive renal fibrosis
06/12/2003US20030109530 Diabetes, insulin resistance, dyslipidemia, obesity, high blood pressure, atherosclerosis, retinopathies and neurodegenerative disorders; synthesis by reacting a biguanide with an aldehyde, semiacetal or acetal in presence of acid catalyst
06/12/2003US20030109527 Novel hydroxy diphenylurea sulfonamides, compositions and intermediates thereof. The hydroxy
06/12/2003US20030109524 Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists
06/12/2003US20030109518 Substituted 1,4-benzodiazepines and uses thereof
06/12/2003US20030109452 Containing phenylalanine, leucine, alanine, and lysine residues are disclosed. The peptides can be used in antibacterial, antifungal, anticancer, and other biological applications.
06/12/2003US20030109437 Peptides and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides derived from the amino acid sequences of such
06/12/2003US20030109436 Wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. DNA sequence codes for cells
06/12/2003US20030109429 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
06/12/2003US20030109416 methods of preventing and treating diseases wherein the involvement of apoptosis has been indicated.
06/12/2003US20030108603 Mixture of protein, hydrophilic polymer, group 1a alkyl sulfate and sugar
06/12/2003US20030108544 Compositions and methods for the diagnosis and treatment of tumor
06/12/2003CA2469385A1 Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
06/12/2003CA2469227A1 New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
06/12/2003CA2469093A1 A novel herbal chemical composition for the treatment of cancer
06/12/2003CA2467435A1 Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
06/11/2003EP1318150A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
06/11/2003EP1317924A1 Kit for reducing aching caused by pde-v inhibitors
06/11/2003EP1317915A1 Hair nourishments and method of screening the same
06/11/2003EP1317531A2 Isolated human phosphatase proteins, nucleic acid molecules encoding them, and uses thereof
06/11/2003EP1317479A2 Methods and compositions for diseases associated with amyloidosis
06/11/2003EP1317454A2 Caspase inhibitors and uses thereof
06/11/2003EP1317453A1 Isoxazoles and their use as inhibitors of erk
06/11/2003EP1317443A2 Chemokine receptor binding heterocyclic compounds
06/11/2003EP1317428A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors
06/11/2003EP1317420A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317417A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317264A2 Combination of lipoic acids and conjugated acids for treating diabetic disorders
06/11/2003EP0892787B1 Novel alpha-hydroxylic acid derivatives, their production and use
06/11/2003CN1423700A Multifunctional polypeptides comprising a binding site to and epitope of the NKG2D receptor complex
06/11/2003CN1423646A Hetero cyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
06/11/2003CN1423645A 维他命d类似物 Vitamin d analogues
06/11/2003CN1423638A Ox (adi) azolyl-hydroxamic acids useful as procollagen C-proteinase inhibitors
06/11/2003CN1423557A Intracorporeal medicaments for photodynamic treatment of disease
1 ... 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 ... 562